Vitrolife AB (OSTO:VITR) Research & Development: kr123 Mil (TTM As of Mar. 2026)


OSTO:VITR Vitrolife AB OSTO:VITR
79 GF Score
Price kr89.65
GF Value kr162.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Research & Development?

Vitrolife AB OSTO:VITR +0.11% 79 Research & Development is kr123 Mil as of Mar. 2026. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vitrolife AB's Research & Development for the three months ended in Mar. 2026 was kr32 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr123 Mil.

Vitrolife AB  (OSTO:VITR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vitrolife AB Research & Development Related Terms

Vitrolife AB Research & Development Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Research & Development Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.00 143.00 127.00 117.00 118.00

Vitrolife AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.00 29.00 27.00 35.00 32.00
OSTO:VITR
79GF Score
Vitrolife AB OSTO:VITR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr123 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr123 Mil mean?
Vitrolife AB (OSTO:VITR) has a Research & Development of kr123 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Research & Development too high?
Vitrolife AB's current Research & Development is kr123 Mil. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Research & Development compare to ABT and SYK?
Vitrolife AB's Research & Development of kr123 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Research & Development is kr123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current Research & Development is kr123 Mil. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Research & Development is kr123 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for OSTO:VITR:

  • Research & Development: kr123 Mil
  • GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score

Get the complete analysis for OSTO:VITR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr89.65
Price
kr162.15
GF Value